Roche pushes late-comer Tecentriq as new liver cancer option

ZURICH (Reuters) - Roche's Tecentriq mixed with Avastin helped liver cancer patients live longer, a boost to the Swiss drugmaker's strategy of expanding its late-to-the-game immunotherapy into niche areas not yet dominated by rivals. Roche said on Monday it will submit overall and progression-free survival data in hepatocellular carcinoma to U.S., European and Chinese regulators in hopes of a speedy approval. The study compared Tecentriq and Avastin with sorafenib, the generic name for Bayer's ..